Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: A United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review

Leukemia and Lymphoma

Volumn 47, Issue 12, 2006, Pages 2584-2589

  Messahel, Boo ^a   Taj, Mary M ^a   Hobson, Rachael ^b   Hadzic, Nedim ^c   Ramsay, Alan ^d   Hann, Ian ^e   Pinkerton, Ross ^f  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UKCCSG Data Centre   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f Mater Hospital   (Australia)

Author keywords

Childhood; Immunodeficiency; Lymphoproliferative disease; Post transplant; Rituximab

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNE DEFICIENCY; INFANT; KIDNEY DYSFUNCTION; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT DURATION; UNITED KINGDOM;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33845586418     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600908349     Document Type: Review

References (28)

1. Hanto, D and Frizzera, G and Gajl-Peczalska, J and Purtilo, D and Klein, G and Simmons, R and (1981) The Epstein-Barr virus (EBV) in the pathogenesis of posttransplant lymphoma Transplant Proc, 13, pp. 756-760.
2. Penn, I and Hammond, W and Brettschneider, L and Starzl, T. (1969) Malignant lymphomas in transplantation patients Transplant Proc, 1, pp. 106-112.
3. Swerdlow, S. (1997) Classification of the posttransplant lymphoproliferative disorders: From the past to the present Semin Diagn Pathol, 14, pp. 2-7.
4. Swerdlow, A and Higgins, C and Hunt, B and Thomas, J and Burke, M and Crawford, D and (2000) Risk of lymphoid neoplasia after cardiothoracic transplantation. A cohort study of the relation to Epstein-Barr virus Transplantation, 69, pp. 897-904.
5. Wilkinson, A and Smith, J and Hunsicker, L and Tobacman, J and Kapelanski, D and Johnson, M and (1989) Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone Transplantation, 47, pp. 293-296.
6. Starzl, T and Nalesnik, M and Porter, K and Ho, M and Iwatsuki, S and Griffith, B and (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy Lancet, 1, pp. 583-587.
7. Pinkerton, C and Hann, I and Weston, C and Mapp, T and Wotherspoon, A and Hobson, R and (2002) Immunodeficiency-related lymphoproliferative disorders: Prospective data from the United Kingdom Children's Cancer Study Group Registry Br J Haematol, 118, pp. 456-461.
8. Berinstein, N and Grillo-Lopez, A and White, C and Bence-Bruckler, I and Maloney, D and Czuczman, M and (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma Ann Oncol, 9, pp. 995-1001.
9. Nguyen, D and Amess, J and Doughty, H and Hendry, L and Diamond, L. (1999) IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients Eur J Haematol, 62, pp. 76-82.
10. Anderson, K and Bates, M and Slaughenhoupt, B and Pinkus, G and Schlossman, S and Nadler, L. (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation Blood, 63, pp. 1424-1433.
11. Maloney, D. (2001) Mechanism of action of rituximab Anticancer Drugs, 12(Suppl 2), pp. S1-S4.
12. Ifthikharuddin, J and Mieles, L and Rosenblatt, J and Ryan, C and Sahasrabudhe, D. (2000) CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab Am J Hematol, 65, pp. 171-173.
13. Reff, M and Carner, K and Chambers, K and Chinn, P and Leonard, J and Raab, R and (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood, 83, pp. 435-445.
14. Maloney, D and Smith, B and Rose, A. (2002) Rituximab: Mechanism of action and resistance Semin Oncol, 29(Suppl 2), pp. 2-9.
15. Alas, S and Emmanouilides, C and Bonavida, B. (2001) Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis Clin Cancer Res, 7, pp. 709-723.
16. Feugier, P and Van Hoof, A and Sebban, C and Solal-Celigny, P and Bouabdallah, R and Ferme, C and (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol, 23, pp. 4117-4126.
17. Hainsworth, J and Litchy, S and Burris, H, III and Scullin, D, Jr and Corso, S and Yardley, D and (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma J Clin Oncol, 20, pp. 4261-4267.
18. Hiddemann, W and Kneba, M and Dreyling, M and Schmitz, N and Lengfelder, E and Schmits, R and (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood, 106, pp. 3725-3732.
19. Vose, J and Link, B and Grossbard, M and Czuczman, M and Grillo-Lopez, A and Gilman, P and (2001) Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol, 19, pp. 389-397.
20. Milpied, N and Vasseur, B and Parquet, N and Garnier, J and Antoine, C and Quartier, P and (2000) Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients Ann Oncol, 11(Suppl 1), pp. 113-116.
21. Choquet, S and Leblond, V and Herbrecht, R and Socie, G and Stoppa, A and Vandenberghe, P and (2006) Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study Blood, 107, pp. 3053-3057.
22. Ghobrial, I and Habermann, T and Ristow, K and Ansell, S and Macon, W and Geyer, S and (2005) Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era Leuk Lymphoma, 46, pp. 191-196.
23. Faye, A and Quartier, P and Reguerre, Y and Lutz, P and Carret, A and Dehee, A and (2001) Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children Br J Haematol, 115, pp. 112-118.
24. Papadaki, T and Stamatopoulos, K and Anagnostopoulos, A and Fassas, A. (2003) Rituximab-associated immune myelopathy Blood, 102, pp. 1557-1558.
25. Dereure, O and Navarro, R and Rossi, J and Guilhou, J. (2001) Rituximab-induced vasculitis Dermatology, 203, pp. 83-84.
26. Westhoff, T and Jochimsen, F and Schmittel, A and Stoffler-Meilicke, M and Schafer, J and Zidek, W and (2003) Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy Blood, 102, pp. 1930.
27. Orjuela, M and Gross, T and Cheung, Y and Alobeid, B and Morris, E and Cairo, M. (2003) A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation Clin Cancer Res, 9, pp. 3945S-3952S.
28. Haque, T and Taylor, C and Wilkie, G and Murad, P and Amlot, P and Beath, S and (2001) Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells Transplantation, 72, pp. 1399-1402.